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ABSTRACT
Previous studies have shown that ZBP-89 (Zfp148) plays a critical role in erythroid lineage devel-
opment, with its loss at the embryonic stage causing lethal anemia and thrombocytopenia. Its
role in adult hematopoiesis has not been described. We now show that conditional deletion of
ZBP-89 in adult mouse hematopoietic stem/progenitor cells (HSPC) causes anemia and thrombo-
cytopenia that are transient in the steady state, but readily uncovered following chemically
induced erythro/megakaryopoietic stress. Unexpectedly, stress induced by bone marrow trans-
plantation of ZBP892/2 HSPC also resulted in a myeloid-to-B lymphoid lineage switch in bone
marrow recipients. The erythroid and myeloid/B lymphoid lineage anomalies in ZBP892/2 HSPC
are reproduced in vitro in the ZBP-89-silenced multipotent hematopoietic cell line FDCP-Mix A4,
and are associated with the upregulation of PU.1 and downregulation of SCL/Tal1 and GATA-1
in ZBP89-deﬁcient cells. Chromatin immunoprecipitation and luciferase reporter assays show
that ZBP-89 is a direct repressor of PU.1 and activator of SCL/Tal1 and GATA-1. These data iden-
tify an important role for ZBP-89 in regulating stress hematopoiesis in adult mouse bone mar-
row. STEM CELLS 2014;32:791–801
INTRODUCTION
The hematopoietic system originates from a
small population of self-renewing hematopoietic
stem cells that differentiate into the various
erythroid, myeloid, and lymphoid lineages. The
hematopoietic lineages tend to be speciﬁed in
a stepwise process of binary decisions, depend-
ent on particular genetic programs under con-
trol of transcription factors. The lineage-
specifying and autoregulatory factors PU.1 and
GATA1 form a master genetic switch that is
responsible for determining the myeloid/lymph-
oid and erythroid lineages [1, 2], respectively,
commonly acting in concert with lineage-
restricted factors such as SCL/TAL1 [3, 4] and
CCAAT/enhancer binding protein a (C/EBPa) [5].
PU.1 and GATA1 mutually inhibit each other’s
expression and transactivation functions, thus
favoring one lineage fate over the other [6].
ZBP-89 (Zfp148) belongs to a novel class of
GC-rich binding transcription factors phyloge-
netically conserved in mammals, which contain
a characteristic array of four Kr€uppel type zinc
ﬁngers [7]. Zebraﬁsh ZBP-89 morphants [8]
and ZBP-89 knockout mice [9] die at the
embryonic stage with severe anemia and
thrombocytopenia. The role of ZBP-89 in adult
hematopoiesis has not been explored.
To investigate its role in adult hematopoi-
esis, we conditionally deleted ZBP-89 in
mouse hematopoietic stem/progenitor cells
(HSPC). We observed an early drop in red
blood cell (RBC) and platelet (PLT) counts in
peripheral blood (PB), and a signiﬁcant reduc-
tion in the number of megakaryocyte/erythro-
cyte progenitors (MEP) in ZBP-89-deﬁcient
bone marrow (BM). The defect in the erythro-
megakaryocytic lineage was, however, tran-
sient under steady state conditions, but was
readily uncovered by chemical induction of
hematopoietic stress. An unexpected reduc-
tion in the myeloid lineage and an increase in
B lymphoid lineage were observed in
ZBP892/2 BM recipients. Transcriptional
proﬁling revealed a signiﬁcant increase in
PU.1 and a reduction in SCL and GATA1 tran-
scripts in HSPC. Similar anomalous hemato-
poietic lineage and transcriptional proﬁles
were observed in vitro when ZBP-89 was sta-
bly silenced in the nonleukemic multipotent
progenitor cell line FDCP-Mix A4 (A4) [10].
Chromatin immunoprecipitation (ChIP) and
luciferase reporter assays showed that ZBP-89
binds to the PU.1, SCL, and GATA1 promoters,
repressing PU.1 and activating SCL and GATA1.
The signiﬁcance of these ﬁndings is discussed.
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REGENERATIVE MEDICINE
MATERIALS AND METHODS
Mice and Cell Lines
Mice expressing the targeted ZBP-89 locus with ﬂanking LoxP
sites (ZBP-89ﬂ/ﬂ) were produced as described [11]. Conditional
deletion of ZBP-89 in the hematopoietic system of mice
(C57BL/6-CD45.21 background) was generated as shown in
Figure 1A. Transgenic mice expressing an interferon-inducible
Cre recombinase (MxCre) (Kuhn et al. [12]) were kindly pro-
vided by Dr. Hanno Hock (MGH Cancer Center). Murine eryth-
roleukemia (MEL) cell line and the nonhematopoietic QM7
cell line, which lacks endogenous ZBP-89 [13], were obtained
from ATCC and maintained in Dulbecco’s modiﬁed Eagle’s
medium containing 10% fetal calf serum. The multipotent A4
cell line was maintained in Iscove’s modiﬁed Dulbecco’s
medium supplemented with 20% horse serum and
Interleukin-3 (IL-3) (100 units/ml, R&D Systems, Minneapolis,
MN). Congenic C57BL/6-CD45.1 mice (6–10 weeks old) were
used as donors for puriﬁcation of wild-type cells and as recipi-
ents for BM transplantation (BMT) experiments. All animal
experiments were performed in accordance with legal and
ethical requirements demanded by law and approved by the
Massachusetts General Hospital Subcommittee on Research
Animal Care.
ZBP-89-Silenced MEL and A4 Cells
21-Mers encoding ﬁve different short hairpin (sh) RNAs (H2 to
H6) (Broad Institute, Cambridge, MA) were used for stable
silencing of mouse wild-type ZBP-89 in MEL cells. Each shRNA
was cloned into the pLK0.1-puromycin plasmid and the plasmid
incorporated into lentivirus using the helper and packaging sys-
tem pDD8.9, pMD.G (VSV-G). Virus-infected MEL cells were
selected by puromycin (5 mg/ml), isolated, and tested for ZBP-
89 silencing by real-time reverse-transcribed polymerase chain
reaction (RT-PCR) and Western blotting. The H5 21-mer, which
produced maximal silencing of ZBP-89 in MEL (Supporting Infor-
mation Fig. S1), was used to stably silence ZBP-89 in A4 cells.
Induction of the Cre Transgene In Vivo
To induce the MxCre transgene, ZBP-89ﬂ/ﬂ-MxCre1 or ZBP-89ﬂ/ﬂ-
MxCre2 control mice were injected intraperitoneally with
polyinosinic-polycytidylic acid (pIpC, Amersham, Biosciences,
Piscataway, NJ) at 20 mg/g dissolved in saline on every other
day for a total of seven doses. Mouse PB and BM cells were har-
vested for analysis at different time points after the last pIpC
injection.
Recombination Analysis
PCR analysis was performed using progenitor colony genomic
DNA. To amplify the ﬂoxed (non-deleted) allele product and
ﬂanking DNA sequence, the forward/reverse primers F1, 50-
AGACCTACGACCCACAGGGTGG-3; R1, 50-GGCTT CTCTCC ACTGT-
GAGTT-30; F2, 50-TGTCCTCTCACCTCTGCACATTCA GCGACAC-30
(between intron 7 and the reverse primer); R2, 50-
TGCGCCACAGACACACATC AGTCTTCAGATCG-30 (at the 30
untranslated region) were used. To amplify the recombined
allele product and Cre gene, the following primers were used:
MH61, 50-GACCAGGTTCGTTCACTCATGG-30; MH63, 50-AGG
CTAAGTGCCTTCTCTACAC-30. The internal control primers were:
IMR0042, 50-CTAGGCCACAGAATTGAAAGATCT-30 and IMR0043,
50-GTAGGTGGAAATTCTAGCATCATCC-30.
Hematologic Analysis and Cell Culture
Blood samples were obtained from mice by tail puncture and
placed in ethylenediaminetetraacetic acid (EDTA)-coated micro-
tubes. Blood counts were performed with a VetScan HM5
(Abaxis, Union City, CA). Murine colony assays were performed
by plating 1 3 105 BM cells/ml of methocult M3434 (Stem Cell
Technologies, Vancouver, BC) in six-well plates in duplicate and
cultured at 37C for 10 days. Burst-forming unit erythroid (BFU-
E), colony-forming-unit granulocyte (CFU-G), CFU-granulocyte-
macrophage (CFU-GM), and granulocyte-erythrocyte-
macrophage-megakaryocyte (CFU-GEMM) colony numbers were
counted based on colony morphology.
Chemical Induction of Hemolytic Anemia and
Thrombocytopenia
One week post-pIpC, mice were injected subcutaneously with
0.4% phenylhydrazine (PHZ; Sigma-Aldrich, St. Louis, MO) in
saline (12 ml/g b.wt.) for 2 consecutive days. Mouse PB was col-
lected for analysis on day 5 and day 15 after PHZ injection. BM
and spleen cells were harvested from control and ZBP-89 CKO
mice (n5 3 in each group) on day 5 post-PHZ injection. To
induce thrombocytopenia, mice were injected intraperitoneally
with 150 mg/kg 5-ﬂuorouracil (5FU) (Sigma-Aldrich, St. Louis,
MO) 1 week post-pIpC, and samples were collected 6 days later.
Hematologic Analysis, Flow Cytometry,
and Cell Sorting
PB cell types were identiﬁed by ﬂow cytometry following stain-
ing with cell-type-speciﬁc antibodies using LSR II cytometer
(BD Biosciences, San Jose, CA). Single-cell suspensions of
spleen and BM cells were obtained as detailed elsewhere [14].
Surface phenotypes of isolated HSPC were as follows: BM-
derived Lineage-negative (Lin2), LSK (Lin2 Sca-11 C-kit1); LT-
HSC (LSK CD1501 CD482); multipotent progenitors (MPP) (LSK
CD341FLK31); common myeloid progenitors (CMP) (Lin2C-
kit1Sca12CD34med CD16/32med); common lymphoid progeni-
tors (CLP) (Lin2C-kitmed Sca1medIL7R1); granule-monocyte pro-
genitors (GMP) (Lin2C-kit1 Sca12CD341CD16/321); MEP
(Lin2C-kit1Sca12 CD342CD16/322); precursor-B-progenitor B
(Pre-Pro-B) (AA4.11 IL-7R1B220MedC-kit1); Pro-B (AA4.11IL-
71B220MedC-kit2); Pre-B (AA4.11IL-71B220hiC-kit2); BM- or
spleen-derived Pro- (CD71highTer119low), Basophilic- (CD71highT-
er119high), and polychromatic (CD71lowTer119high) erythroblasts
[15]. Quantitative analysis of the distinct stages of erythroblast
development was conducted as described [16]. Brieﬂy, BM or
spleen cells were ﬁrst blocked with rat anti-mouse CD16/32 (BD
Biosciences, San Jose, CA) for 15 minutes, stained with the
labeled rat anti-mouse antibodies FITC-ter119, APC-CD44, APC-
Cy7 CD45, APC-Cy7 CD11b, and APC-Cy7 GR1 (BD Biosciences,
San Jose, CA), then subsequently stained with 7-AAD (BD Bio-
sciences, San Jose, CA) before cell analysis using ﬂow cytometry.
In chimeric mice, PB and HSPC were stained with both Paciﬁc
blue-anti-CD45.2, PE-Cy7-anti-CD45.1 and the lineage-speciﬁc
FITC-anti-CD41, PE-anti-CD11b, PE-CY5-anti-CD3, and APC-anti-
B220 antibodies, and the dual-positive (Paciﬁc blue-CD45.21
and lineage-speciﬁc cell populations) were gated and quantiﬁed.
Wild-type or ZBP-89-silenced A4 cells at various passages (12–24
weeks) were immunostained after 1 week in culture with mAbs
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to the lineage-speciﬁc markers CD41, CD11b, CD3, and B220 fol-
lowed by ﬂow cytometry.
Total RNA Isolation and RT-PCR
Total RNA was extracted from fractionated BM progenitors or
from A4 cells with the RNAqueous-4PCR kit (AMBION INC,
Austin, TX). For each experiment, BM progenitor-derived RNAs
from two ZBP-89 CKO or two control mice were pooled.
Reverse transcription of BM progenitor- or A4-derived RNA
was performed with the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Grand Island, NY). RT-PCR
was run on Stratagene300 (Agilent Technologies, Santa Clara,
CA) using Brilliant SYBR Green QPCR Master Mix (Agilent
Technologies, Santa Clara, CA). Sequences for the primers
used are as follows. ZBP89 RTF, 50-CGGCATAGACGAAATGCA
GTC-30; ZBP89 RTR, 50-CCTGGTGAGGCAAACTTCGAT-30; SCL RTF,
50-CAC TAGGCAGTGGGTTCTTTG-30; SCL RTR, 50-GGTGTGAGGAC
CATCAGAAATCT-30; GAPDH RFF, 50-AGGTCGGTGTGAACGGA
TTTG-30; GAPDH RTR, 50-TGTAGACCATGTAGTTGA GGTCA-30;
GATA1 RTF, 50-TGGGGACCTCAGAACCCTTG-30; GATA1 RTR, 50-
GGCTGCATTTGGGGAAGTG-30; PU.1 RTF, 50-GGACATGGTGTG
CGGAGAA-30; PU.1 RTR, 50-AGAAA GCCATAGCGATCACTACT-30;
TIF1c RTF, 50-AGATAATGCA AGTGCAGTTGGT-30; TIF1c RTR, 50-
ACGTCAATCTATCACACGTTTCA-30; C/EBPa RTF, 50-AGGACACG
GGGACCATTAG-30; C/EBPa RTR, 50-TAGACGTGCACACTGCCATT-30;
FOXO1 RTF, 50-ATGCTCAATCCAGAGGGAGG-30; FOXO1 RTR, 50-AC
TCGCAGGCCACTTAGAAAA-30; Gﬁ1 RTF, 50-CCCTTTGCGTGCGAG
ATGT-30; Gﬁ1 RTR, 50-CACTGCCTTGTGTTGCTCCA-30; C-myb RTF,
50-CAGAAGAGGAGGACAGAATCATTT; C-myb RTR, 50-TTCCAGTG
GTTCTTGATAGCATTA-30; FOG1 RTF, 50-CAGAGCCTTATCCCCTGAG
AG-30; FOG1 RTR, 50-CGGCTTCT TCAGTTAGGACCT-30.
BM Repopulation Assays
CD45.21 ZBP-89ﬂox/ﬂox-Mx-Cre2 or ZBP-89ﬂox/ﬂox-Mx-Cre1 BM
cells mixed with competitor wild-type CD45.1 BM cells in a
1:1 ratio (a total of 2 3 106 cells) were injected intrave-
nously into the lateral tail vein of congenic age-matched
CD45.11 mouse recipients (n5 5 per genotype) that were
lethally irradiated 1 day before BMT. Six weeks later, 20 mg/g
pIpC were injected into recipient mice every other day (for a
total of seven doses), following which PB cells and BM HSPC
were harvested at different times and analyzed for expres-
sion of CD45.1 and CD45.2 alleles. For secondary BMT,
CD45.21 ZBP-89-excised BM cells were harvested from pri-
mary recipients 7 months after the last pIpC dose, and 2 3
106 cells were injected into 6-week-old irradiated CD45.11
recipient mice (n5 5 per genotype). Reconstitution of sec-
ondary recipients was analyzed 6–36 weeks after BMT.
ChIP Assays
This was carried out as described [17]. Brieﬂy, 5 3 106 MEL cells
were cross-linked with 1% (vol/vol) formaldehyde, the reaction
stopped with glycine, and washed cells pelleted then
.
Figure 1. Generation and PB phenotype of ZBP-89 CKO mice.
(A): Strategy for inducible inactivation of ZBP-89 in hematopoietic
stem/progenitor cell. Schematic of targeted ZBP-89 exons 8 and 9
(in white), with noncoding region of exon 9 in gray. Restriction
sites (P, PstI; E, EcoR1; B, BamH1; H, HindIII; X, Xba1), LoxP sites
(open arrows), and FRT sites (closed arrows) are indicated. F1, F2,
R1, and R2 represent approximate position and orientation of the
primers used in PCR. TK, thymidine kinase; NEO, neomycin. Sizes
of the left (3.1 kb) and right (5.6 kb) vector arms are shown. (B):
PCR genotyping showing deletion of the ﬂoxed segment of ZBP-
89 in single CFU-GM stem cell colonies 8 weeks after pIpC treat-
ment. Lanes 1–4, bone marrow colonies from control (ZBP-89ﬂ/ﬂ-
MxCre2) mice, and lanes 5–8 are colonies from ZBP-89 CKO (ZBP-
892/2-MxCre1) mice post-pIpC. Interleukin-2 (IL2) is included as
internal control. (C): PB white blood cells (WBC)-, RBC-, and pla-
telet counts and hemoglobin (Hgb) level 1–8 weeks after pIpC in
six control mice (ﬁlled diamonds, dotted lines) and in seven ZBP-
89 CKO mice (open squares, solid lines). Results are shown as
mean6 SD, from two independent experiments. *, p< .05; **,
p< .01. (D): CD411, CD11b1, CD31, and B2201 cells in PB from
normal (black bars) and ZBP89 CKO mice (white bars) 3 weeks
after pIpC injections (mean6 SD, n5 6 in each group). Abbrevia-
tions: PB, peripheral blood; RBC, red blood cell; WBC, white
blood count.
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resuspended in lysis buffer. Following homogenization, the nuclei
were sonicated on ice to a DNA size of 200–800 bp. Protein-
DNA complexes were immunoprecipitated using an anti-ZBP-89
antibody (SC-19408; Santa Cruz, Biotechnology, Dallas, Texas) (or
immunoglobulin G [IgG] as a negative control), and the DNA-
protein complexes collected by binding to A/G plus-agarose
beads. Washed beads were eluted in 1% SDS/0.1 mM NaCHO3.
DNA was reverse-crosslinked by incubation at 68C overnight
then puriﬁed using QIAGEN quick PCR puriﬁcation kit. PCR was
performed using 10% (3 ml) of the bound DNA fraction from the
chromatin precipitate or 1% (1 ml) of the input DNA fraction. The
murine SCL 1a/b promoter fragments (22,000 to 11 bp) con-
taining the ZBP-89 element were ampliﬁed using the forward
primer 50-TCCCAACGTGAGCGCTCAGCC-30 and the reverse primer
50-TGTGCGCCGCCGAGATAAGG-30 for 1a region, and the forward
primer 50-TTCCTCCGTCTTTCCCCATGC-30 and the reverse primer
50-AGCACTCTCAACCCGGCCGCC-30 for 1b region. The murine
PU.1 3.4 kb HindIII UTR fragments containing the ZBP-89 ele-
ment were ampliﬁed using the primers F1: 50-ACCCCGG
GGTTGAAGGAACAC-30, R1; 50-TCTCCAGAAAGCCTGTTGCTGTCAG-
30; F2, 50-TAACCCCTGCACATGAAAGCC-30, and R2, 50-TCTGGG
CAGGGTCAGAGTGCC-30. The murine 129bp fragment containing
the ZBP-89 binding site in G1HE was ampliﬁed using the forward
primer 50-tcccttatctatgccttccca-30 and the reverse primer 50-
atgaagggtgcctctaaggac-30. PCR products were separated in 2.0% aga-
rose gels containing 0.5 mg/ml ethidium bromide.
Site-Directed Mutagenesis
Mutations in the ZBP-89 binding site of murine SCL 1a pro-
moter were generated by overlapping PCR, changing the wild-
type ZBP-89 Ia binding site core sequence 50-cgcttat
cgGGGGcggggcc-30 to 50-cgcttcgGAAGcGgggcc-30. PCR reactions
were performed using WT forward primer (WTFP): 50-
GGGGTACCTCAGTTAGCGGTGAAGGCTCATG-30 (tagged KpnI site
italicized) and mutant reverse primer: 50-GGCCCGCCAGC
TTCCGATAAGCG-30, to generate the ﬁrst fragment, and the
mutant forward primer: 5-CGCTTATCGGAAGCTGGCGGGCC-30,
and WT reverse primer (WTRP): 50-CCGCTCGAGACCCGGCCG
CCCGCACACACC-30 (tagged XhoI site italicized) to generate the
second fragment. DNAs from both PCR ampliﬁcations were gel
extracted and used in overlapping PCR using WTFP and WTRP,
and the ﬁnal product was KpnI/XhoI restricted then inserted
into the KpnI/XhoI-digested pGL2 vector. XL1-Blue competent
cells were transformed with ligation mix, plated on LB Ampicil-
lin plates, and incubated overnight at 37C. Colonies were
screened and clones conﬁrmed by DNA sequencing. A similar
strategy was used in replacing WT ZBP-89 core binding site 50-
ggctccctctCCCCcgtctcttc-30 in Ib with 50-ggctccctctCTTCcgtctcttc-
30.
Luciferase Assay
The pXP-214 kb/-0.334 kb/Luc plasmid containing the 3.5 kb
215/-14 URE cloned 50 of the PU.1 minimal promoter was
cloned upstream of the Luciferase (Luc) reporter [18]. A con-
struct containing a 1.5 kb segment 50 of SCL promoter 1a in
addition to promoter 1a and 1b was cloned upstream of Luc
reporter gene in the pGL2 vector [19] (SCL-pGL2 plasmid). Con-
trol and ZBP89-silenced MEL cells were transiently transfected
with SCL-pGL2 or pXP-214 kb/-0.334 kb/Luc plasmids. QM7
cells intrinsically lacking ZBP-89 were cotransfected with Luc
reporter constructs prepared using the wild-type G1HE-(124–
235)-Luc or G4 mutant G1HE-(124–235)-Luc reporter [13] and
an expression plasmid encoding wild-type mouse ZBP-89. Trans-
fected cells were harvested, washed twice in PBS, pelleted,
lysed with 300 ml of lysis buffer (Promega Inc., WI) for 30
minutes at room temperature, and lysate centrifuged for 10
minutes at 13,000 rpm. Luciferase assays were carried out on
20 ml of each cell lysate supernatant and light units measured
in a Berthold LB9507 luminometer (Berthod, Germany). Rela-
tive light units were normalized for transfection efﬁciency
against b-Galactosidase (b-Gal) values obtained from 20 ml of
each supernatant. b-Gal assays were performed according to
the manufacturer’s instructions (Applied Biosystems, Grand
Island, NY).
Statistical Analysis
The signiﬁcance of the difference between groups in the in
vitro and in vivo experiments was determined by analysis of
variance followed by a one-tailed Student’s t test. Data are
expressed as the mean6 SD, with p-values of <0.05 consid-
ered signiﬁcant.
RESULTS
Anemia and Thrombocytopenia in ZBP-89
CKO Mice
We conditionally inactivated ZBP-89 in the mouse hematopoi-
etic system by breeding a ZBP-89ﬂ/ﬂ C57BL/6 mouse strain
[11] with interferon-inducible Mx-Cre transgenic C57BL/6 mice
[12] (Fig. 1A), followed by administration of poly(I)-poly(C)
(pIpC) every other day for a total of seven injections. PCR of
genomic DNA from control (ZBP-89ﬂ/ﬂ-MxCre2) and ZBP-89ﬂ/ﬂ-
MxCre1 mice showed undetectable amounts of ZBP-89ﬂ/ﬂ in
single BM-derived CFU-Granulocyte-Macrophage (CFU-GM)
colonies transduced with the Cre gene, indicating nearly com-
plete excision of both ZBP-89ﬂ/ﬂ alleles (Fig. 1B).
PB cells obtained weekly in the ﬁrst 4 weeks and at 2
months after the last pIpC injection showed a signiﬁcant drop in
RBC and hemoglobin (Hgb) and in PLT counts and in CD411
megakaryocytes in ZBP-892/2-MxCre1 mice but not in control
(ZBP-89ﬂ/ﬂ-MxCre-) mice 3 weeks after the last pIpC injection (Fig.
1C, 1D). No signiﬁcant changes in peripheral white blood count
(WBC), or circulating myeloid (CD11b1), lymphoid T- (CD31) or
B- (B2201) cells were detected (Fig. 1C, 1D). Consistently, BM
colony-forming assays showed reduced ZBP-89-deﬁcient BFU-E
and GEMM, but not CFU-GM, CFU-M, or CFU-G colonies (Sup-
porting Information Fig. S2A). Peripheral RBC and PLT counts
returned to normal at 4 and 8 weeks post-pIpC (Fig. 1C), with
an associated normalization of BM BFU-E and CFU-GEMM colony
counts of ZBP-89 CKO mice (Supporting Information Fig. S2B).
Changes in HSPC and Their Transcriptional Profile
The percentage of ZBP-89-deﬁcient MEP was signiﬁcantly
reduced 3 weeks post-pIpC (Fig. 2A), but no change was
detected in ZBP-89-deﬁcient LT-HSC, MPP, CMP, CLP, and GMP.
The transcriptional proﬁles of key transcription factors
known to regulate hematopoietic lineage commitment were
measured in BM progenitors from ZBP-89-deﬁcient and sufﬁ-
cient animals (Fig. 2B). RT-PCR carried out on mRNA derived
from sorted ZBP-89-deﬁcient MPP, CLP, CMP, GMP, and MEP
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revealed a signiﬁcant induction of PU.1 in MPP, CLP, CMP, and
MEP, and of FOXO1 in ZBP-89-deﬁcient MPP and CLP. In con-
trast, SCL/TAL1 and GATA1 levels were signiﬁcantly reduced by
60%–80% in ZBP-89-deﬁcient MPP, CMP, and MEP but not in
CLP or GMP. TIF1c was only suppressed in MEP, while C/EBPa
was suppressed in MPP, CMP, and GMP (Fig. 2B). As expected,
ZBP-89 mRNA levels were minimal in HSPC derived from ZBP-
89 CKO mice (Fig. 2B).
ZBP-89 Contributes to the Erythro- and
Megakaryopoietic Reserve in the Adult
In response to erythroid stress in adults, the rate of RBC produc-
tion rapidly increases from its steady state level [20]. We eval-
uated the response to acute depletion of RBC or PLT in ZBP-89
CKO and control mice. Phenylhydrazine (PHZ) induced a signiﬁ-
cant (50%) drop in circulating RBC counts (Fig. 3A) and in BM
BFU-E colonies (Supporting Information Fig. S2C), but not in PB
PLT counts (Fig. 3A) or CFU-GEMM colonies (Supporting Informa-
tion Fig. S2C) from ZBP-89 CKO mice. Erythroblast development
was examined using two methods [15, 16], both of which
showed a signiﬁcant reduction in pro- and basophilic erythro-
blasts of ZBP-89 CKO mice (Fig. 3B, Supporting Information Fig.
S3), in parallel with an increase in pro- and basophilic erythro-
blasts in spleen of ZBP-89 CKO mice (Fig. 3B, Supporting Informa-
tion Fig. S3A, S3B). Polychromatic erythroblasts in spleen were
increased 1.6-fold in ZBP-89 CKO mice when quantiﬁed by one
method [15] (Fig. 3B) but not the other [16] (Supporting Informa-
tion Fig. S3B). There was also a signiﬁcant increase in spleen size
on day 5 after PHZ injection in ZBP-89 CKO mice (Supporting
Information Fig. S4). These changes were insufﬁcient, however,
to prevent stress-induced anemia on day 5, but might have con-
tributed to the normalization of RBC, Hb, and Hct by day 15 after
PHZ injection (Supporting Information Fig. S5).
PB PLT count, but not RBC or WBC counts, also signiﬁ-
cantly decreased in ZBP-89 CKO mice upon acute administra-
tion of 5-ﬂuorouracil (5-FU), which depletes immature
megakaryocytic progenitors and megakaryocytes in endomito-
sis [21] (Fig. 3C). Fluorescence-activated cell sorting analysis
further conﬁrmed that the megakaryocyte lineage marker
CD41 was markedly reduced in PB following 5-FU treatment
(Fig. 3D), with no signiﬁcant changes in PB myeloid (CD11b1),
T- (CD31), or B-cells (B2201).
ZBP-89 Deletion Results in Reciprocal Changes in the
Myeloid- and B-Cell Lineages in BM Repopulation
Assays
CD45.21 BM cells from ZBP-89-excised (ZBP-89-ﬂ/ﬂ-MxCre1) and
control (ZBP-89ﬂ/ﬂ-MxCre-) mice were transplanted into con-
genic lethally irradiated CD45.11 recipients that were then
treated with pIpC starting 6 weeks after transplantation (Fig.
4A). The contribution of ZBP-89-excised CD45.21 hematopoi-
etic stem cells to PB and BM cells was monitored by surface
expression of the CD45.2 allele in HSPC and in PB (Fig. 4B–4E).
The proportion of CD45.11 and of CD45.21 cells in recipients 3
weeks after primary BMT was equivalent (Fig. 4B, upper panel).
Since partially differentiated, yet multilineage hematopoietic
precursors continue to generate mature cells for up to 3
months post-BMT, we measured the percentage of progenitors
and differentiated blood cells that descended from donor and
competitor precursors up to 8 months after BMT, thus ensuring
that all mature blood cells derive from primitive hematopoietic
stem cells [22, 23]. ZBP-89-excised CD45.21 cells contributed
comparably to peripheral myeloid and lymphoid cells (CD11b1,
CD31, and B2201) in recipient mice for 4.5 months (Fig. 4C).
Afterward, the CD45.21 CD11b1 PB pool dropped signiﬁcantly
(by approximately two-third) with a reciprocal increase in the
B2201 pool, but with no changes in number of CD31 cells. At
3 weeks post-pIpC, CD45.21 CD411 megakaryocytic cell num-
bers signiﬁcantly dropped, but normalized at week 6 post-pIpC
Figure 2. Transcription factor proﬁles of bone marrow (BM)
hematopoietic stem/progenitor cell from ZBP-89 CKO and control
mice 3 weeks after the last dose of pIpC. (A): Histograms
(mean6 SD, n5 3) showing the percentage of LT-HSC, MPP, CLP,
CMP, GMP, and MEP in fractionated BM cells from ZBP-89 CKO
and in control mice. (B): RT-PCR analysis of transcription factors in
BM progenitors derived from ZBP-89 CKO and control mice (bars
are colored as in A). Results are from two independent experi-
ments, each representing pooled samples from two mice in each
group. *, p< .05; **, p< .01. Abbreviations: CLP, common lymph-
oid progenitor; CMP, common myeloid progenitor; GMP, granule-
monocyte progenitor; MEP, megakaryocyte/erythrocyte progenitor;
MPP, multipotent progenitor.
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onward (Fig. 4C), as in the steady state (Fig. 1C). RBC levels
were normal but their origin was not determined in the chi-
meric mice as RBC lack CD45 expression. A signiﬁcant reduc-
tion in GMP with a corresponding increase in Pre-B and a drop
in Pre-Pro-B was observed in the BM, 38 weeks post-pIpC (Fig.
4D, 4E). These changes likely account for the reciprocal altera-
tions in ZBP-89-excised CD45.21 CD11b1 and CD45.21 BB201
cells in PB. No changes were detected in the LT-HSC, CMP,
MEP, or Pro-B pools (Fig. 4D, 4E). The decrease in the Pre-Pro-B
cells and the increase in the Pre-B population (Fig. 4E) may
suggest that proliferation of ZBP-89-excised B-cell progenitors
in the stages from Pro-B to Pre-B cells is accelerated.
We next examined the capacity of ZBP-89-excised CD45.21
BM HSC for long-term reconstitution of adult hematopoiesis by
serial transplantation. Donor CD45.21 ZBP-892/2 or ZBP-89ﬂ/ﬂ
BM (as control) cells were injected into lethally irradiated
CD45.11 recipient mice. The multilineage engraftment poten-
tial was assessed over an 8-month period. A reduction in PB
CD11b1CD45.21 cells and an increase in B2201CD45.21 cells
were again seen in cells derived from ZBP-89-excised HSPC,
beginning earlier (at week 6-post-transplantation) (Fig. 5A) ver-
sus 24 weeks following primary BMT (Fig. 4C). Examination of
BM hematopoietic progenitors at 7.5 months also showed per-
sistence in the contraction of the GMP pool size and the
increase in the Pre-B compartment (Fig. 5B, 5C).
Transcriptional Deregulation in
ZBP-89-Excised HSPC
RT-PCR analysis performed on RNA derived from sorted ZBP-
89-deﬁcient BM HSPC from secondary BM transplant recipi-
ent mice at 36 weeks post-transplantation showed persistent
upregulation of PU.1 and downregulation of GATA1 and SCL/
TAL1 in MPP, CMP, and MEP, upregulation of FOXO1 in MPP
and downregulation of C/EBPa in MPP, CMP, and GMP, and
of Gif1 in MPP and FOG-1 in MEP (Fig. 5D). No signiﬁcant
changes in C-myb or Tif1c expression were seen.
The Hematopoietic Lineage Anomalies in ZBP-89 CKO
Mice Are Reproduced In Vitro in ZBP-89-Silenced
Multipotent A4 Cells
As previously described [24], immunophenotyping of wild-
type A4 cells by ﬂow cytometry showed that the bulk
express the B lineage marker B220, the myeloid lineage
marker CD11b, and the megakaryocytic marker CD41 (Table
1). Stable silencing of ZBP-89 in A4 progenitors caused sig-
niﬁcant reductions in expression of CD41 and CD11b but
increased expression of B220, mirroring the changes
observed under BMT stress conditions in vivo. RT-PCR
.
Figure 3. Effect of ZBP-89 CKO on stress erythropoiesis and
thrombopoiesis. (A): Histograms (mean6 SD, n5 4) showing the
effect of phenylhydrazine (PHZ)-induced hemolysis on RBC and
PLT counts in PB of ZBP-89 CKO mice (white bars here and in C,
D) compared to control mice (black bars here and in C, D). (B):
Representative ﬂuorescence-activated cell sorting (FACS) analyses
of BM proerythroblasts (CD71highTer119low) and basophilic eryth-
roblasts (CD71highTer119high) (left) and basophilic- and polychro-
matic (CD71lowTer119high) erythroblasts in spleen (right) of control
and ZBP-89 CKO mice, 2 weeks after the last pIpC injection and 5
days after PHZ. Numbers for each box reﬂect percentages of the
gated cells, with each representing the mean value from four
mice in each group. (C, D): Histograms (mean6 SD, n5 4) show-
ing the effect of 5-ﬂuorouracil (5-FU)-induced platelet depletion
on circulating platelet-, white blood cells (WBC)-, and RBC counts
(C), and on surface phenotype, analyzed by FACS from ZBP-89
CKO and control mice, 2 weeks after the last pIpC treatment and
6 days after 5-FU (D). *, p< .05. Abbreviations: BM, bone mar-
row; PB, peripheral blood; RBC, red blood cell; WBC, white blood
count.
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analysis performed on RNA derived from ZBP-89-sufﬁcient
and deﬁcient A4 progenitors again showed downregulation
of GATA1, SCL/TAL1, and C/EBPa and upregulation of PU.1
and FOXO1 in ZBP-89-silenced cells (Fig. 5E).
ZBP-89 Acts as a Direct Transcriptional Repressor of
PU.1 and Activator of SCL and GATA1
Induction of PU.1, and suppression of SCL in ZBP-89-silenced
BM progenitors, suggested these two factors might be direct
downstream targets of ZBP-89, as has been previously shown
for GATA1 [13]. This was tested (Fig. 6A–6I) using ChIP [17]
and luciferase reporter assays in WT and ZBP-89-silenced MEL
cells or in the nonhematopoietic QM7 cells, which lack endog-
enous ZBP-89 [13], using the known transcriptional regulation
of GATA1 by ZBP-89 as a positive control (Fig. 6A–6C).
Expression of PU.1 is regulated primarily by a 215/14 kb
upstream regulatory region (URE) (Fig. 6D), deletion of which
reduces PU.1 expression by 80% in mice [25]. C/EBPa binds to
URE and prepares an adjacent 212 kb enhancer for autoregu-
latory PU.1 chromatin entry, thus driving myeloid-speciﬁc
PU.1 expression [26]. A Genomatix search [27] identiﬁed three
potential ZBP-89 binding sites in the 215/14 kb URE (Fig. 6E),
two of which overlap. ChIP assays conﬁrmed binding of ZBP-
89 to URE (Fig. 6D, lower panel). Luciferase reporter assays
carried out on WT and ZBP-89-silenced MEL transiently trans-
fected with the pXP-214 kb/-0.5 kb/Luc plasmid [25] (Fig. 6E),
revealed a 2.5-fold induction of PU.1 when ZBP-89 was
silenced (Fig. 6F).
Tissue-speciﬁc expression of murine (and human) SCL is
driven by two minimal promoters la and lb [28] (Fig. 6G).
Promoter Ia restricts SCL expression to the erythroid lineage
[19], and Ib directs SCL expression in CD341 hematopoietic
progenitors [29]. A Genomatix search revealed two potential
ZBP-89 binding sites in the immediate 50 regions of 1a and
1b in SCL (Fig. 6H). ChIP assays in WT MEL cells showed that
ZBP-89 binds speciﬁcally to DNA fragments containing these
regions upstream of the respective promoter (Fig. 6G, lower
panel). Luciferase reporter assays showed that the
22kbSCL1a1b region drove luciferase expression in WT MEL
cells, but minimally in ZBP-89-silenced MEL (the residual
activity is likely explained by the incomplete 80% silencing of
ZBP-89). Nucleotide substitutions of one or both consensus
ZBP-89 binding motifs reduced luciferase reporter activity by
50% and by 60%, respectively (Fig. 6I), suggesting that ZBP-
89 binding to the proximal site plays a greater role in SCL
induction in the WT MEL cellular context.
.
Figure 4. PB cell counts and percentage of immature hemato-
poietic lineages in 10 BM transplant recipients. (A): Schematic of
the experimental design: BM cells (CD45.21) from ZBP-89 CKO
and control mice were mixed with wild-type (WT, CD45.11) BM
cells at a 1:1 ratio and the mixture injected into irradiated wild-
type (WT) recipients (CD45.11). pIpC injections started 6 weeks
later and over a 2-week period. PB samples were analyzed at 3–
32 weeks after the last pIpC dose and BM was examined at 38
weeks. (B): Isolation of lineage-speciﬁc CD45.21CD45.12 PB cells
from control recipients of 10 BM at 3 weeks post-pIpC. (C): Per-
centage of PB megakaryocytes (CD411), myeloid- (CD11b1), T-
(CD31), and B (B2201)-cells in the CD45.21 population of ZBP-
892/2 and control (ZBP-89ﬂ/ﬂ) mice at the indicated times after
pIpC injections. (D): Histograms showing percentage of the differ-
ent immature hematopoietic lineages in the CD45.21 BM popula-
tion of ZBP-892/2 (mean6 SD, n5 7) and control mice
(mean6 SD, n5 8) 38 weeks after pIpC treatment. (E): Histo-
grams (mean6 SD, n5 4) showing the percentage of Pre-Pro-B
cells, Pro-B cells, and Pre-B cells in the CD45.21 BM population
of ZBP-892/2 and control mice 38 weeks after pIpC treatment. *,
p< .05; **, p< .01. Abbreviations: BM, bone marrow; CMP, com-
mon myeloid progenitor; GMP, granule-monocyte progenitor;
HSPC, hematopoietic stem/progenitor cell; MEP, megakaryocyte/
erythrocyte progenitor; PB, peripheral blood.
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DISCUSSION
The role of ZBP-89 in embryonic development of the hema-
topoietic system has been previously described in zebraﬁsh
and mouse embryos [8, 9]. Using a conditional knockout
model of ZBP-89 in adult mice, we now show that ZBP-89
plays a previously unrecognized role in stress hematopoiesis
in the adult.
Excision of ZBP-89 in adult mice resulted in the overt
drop in circulating RBC and PLT counts by 3 weeks post-pIpC
but spared the other hematopoietic lineages, despite the
efﬁcient excision of ZBP-89 in the respective hematopoietic
progenitors. Anemia and thrombocytopenia were associated
with a signiﬁcant reduction in MEP and in early and late ery-
throid progenitors in BM, ﬁndings that were also observed
in the absence of the master erythroid megakaryocytic regu-
lator GATA1 [30]. This is likely secondary to the higher mye-
loid potential of CMP and MPP, resulting from reduced
GATA1 and increased PU.1 expression in these progenitors
[1, 6, 31, 32].
Figure 5. Hematopoietic lineages and their transcriptional proﬁles in 20 BM transplant recipients and in ZBP-89-silenced A4 cells. (A):
Percentages of the different HSPC lineages in CD45.21 PB at different times after 20 BM transplantation. Results given are mean6 SD
(n5 5 mice in each group). (B, C): Histograms (mean6 SD, n5 4) showing the percentages of the different BM progenitors in CD45.21
BM from 20 BMT recipients at 30 weeks post-transplantation from control (black bars) and CKO mice (white bars). *, p< .05; **,
p< .01. (D): Histograms (mean6 SD, n5 2 independent experiments) showing gene expression proﬁles in BM progenitors from ZBP-89-
deﬁcient cells 36 weeks after 20 BMT (white bars) relative to that in control mice (black bars). For each experiment, RNAs from two
mice in each group were pooled for RT-PCR. *, p< .05; **, p< .01. (E): Histograms (mean6 SD, n5 2 experiments) showing gene
expression proﬁles in control and ZBP-89-silenced A4 progenitors. *, p< .05. Abbreviations: BM, bone marrow; CMP, common myeloid
progenitor; GMP, granule-monocyte progenitor; HSPC, hematopoietic stem/progenitor cell; MEP, megakaryocyte/erythrocyte progenitor;
PB, peripheral blood.
Table 1. Immunophenotype of wild-type and ZBP-89-silenced
FDCP-A4 (A4) cells
Cell lineage
Surface
marker
Percent positive cells
p valueA4 H5-A4
Megakaryocytes CD41 80.36 5.1a 55.1 6 11.1 .022
Myeloid CD11b 92.8 6 1.5 72.0 6 12.2 .043
B cells B220 47.9 6 8.1 77.2 6 2.2 .004
T cells CD3 1.6 6 0.7 1.5 6 1.9 .99
aNumbers represent the mean6 SD of three independent
experiments.
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The anemia and thrombocytopenia observed in ZBP-89
CKO mice were however transient, with normalization of RBC
and PLT counts in PB 4 and 8 weeks post-pIpC, in parallel
with normalization of BFU-E and CFU-GEMM BM colonies at 8
weeks post-pIpC. This recovery is unlikely to derive from pro-
genitors that escaped Cre-excision of the ZBP-89 gene, since
ZBP-89 excision in hematopoietic progenitors is still demon-
strable 36 months later (Fig. 5D). A more likely explanation is
that loss of ZBP-89 in BM progenitors can be overcome in
vivo in the steady state. The redundancy sometimes observed
in genetic ablation models is usually explained by the pres-
ence of a functionally related gene. Whether ZBP-99
(ZNF281), the other known member of the ZBP-89 family [33],
can compensate for loss of ZBP-89 in early BM erythro-
megakaryocytic progenitors in the steady state will require
further study.
The defect in the erythro-megakaryocytic lineages in ZBP-89
CKO mice can readily be exposed under stress (Fig. 3). Hemo-
lytic stress normally induces expansion of erythroid progenitors
in the spleen, driven largely by rapid proliferation of erythroid
progenitors [34]. The response to stress erythropoiesis in mice,
which occurs mainly in the spleen [35], was evident in ZBP-89
CKO mice, but insufﬁcient to prevent overt anemia. Erythropoie-
sis in the spleen is a molecularly distinct process from BM
erythropoiesis, dependent on the glucocorticoid receptor [36],
c-Kit [35], and BMP4/Smad5 [37], which may explain the differ-
ential response to stress in the spleen versus that in BM of
ZBP-89 CKO mice. Impaired development and maturation of the
erythroid lineage in BM under stress in ZBP-89 CKO mice has
also been observed in GATA1 CKO mice [30] and to a lesser
degree in SCL/TAL1 CKO mice [38], suggesting that abnormal
stress erythropoiesis in ZBP-89 deﬁcient BM erythroid
Figure 6. ZBP-89 is a transcriptional regulator of GATA1, PU.1, and SCL. (A): Schematic of a genomic segment containing mouse GATA1
locus, with two cell-type-speciﬁc ﬁrst exons (IT and IE), ﬁve coding exons (II–VI), and the G1HE region. The other cis-regulatory elements
(double GATA and CACCCs) are not shown. Lower panel, chromatin immunoprecipitation (ChIP) assays showing speciﬁc binding of ZBP-
89 to the 50 region of the GATA1 gene hematopoietic enhancer (G1HE) (which allows GATA1 expression in erythroid lineage). (B): WT
and mutant G1HE (G1HE-(124–235)-Luc in which one of the G5 string comprising the ZBP-89 core binding motif is deleted) reporter con-
structs used (see Materials and Methods). (C): Histograms (mean6 SD, n5 2) showing luciferase (Luc) activity in ZBP-89-transfected
QM7 cells driven by WT or mutant G1HE (where the ZBP-89 site is mutated). Background luciferase activity was obtained using the con-
trol (C) promoter-less vector pGL2. (D): Schematic of a genomic segment containing the nontranslated region of PU.1, the minimal pro-
moter (white bar), and the ﬁve coding exons (in black). Transcription start site (11) and direction (horizontal arrow) are shown. Lower
panel, ChIP assays showing speciﬁc interaction of ZBP-89 with two PCR products in the 215/214 URE of PU.1. Normal IgG is used as
negative control, and input DNA used as a positive control. (E): pXP-214 kb/-0.334 kb/Luc plasmid containing the 3.5 kb 215/214 URE
(in black) cloned upstream of the PU.1 minimal 0.5 kb promoter (in white) driving Luc reporter (in gray). Position and sequence of the
three predicted ZBP-89 binding sites (core motif capitalized) in 215/14 URE are shown. (F): Histograms (mean6 SD, n5 2) showing Luc
activity in WT and ZBP-89-silenced MEL cells driven by 215/14 URE. In C, F, I, relative units represent Luc activity normalized against b-
Gal values. (G): Schematic of a genomic segment containing mouse SCL, comprising seven exons, with noncoding exons in white. Lower
panel, ChIP assays showing speciﬁc interaction of ZBP-89 with 1a or 1b promoter regions. (H): Schematic of the construct containing
promoters la and lb of SCL cloned upstream of Luc in SCL-pGL2 vector. The two predicted ZBP-89 binding sites are shown. Position and
nature of substitution of the two central pyrimidines in the ZBP-89 binding motif of la and lb are indicated above and below the respec-
tive sequence. Exons 1a and 1b are shown as white boxes. (I): Histograms (mean6 SD, n5 2) showing Luc activity driven by 22 kb to
11 DNA region of WT SCL or by SCL in which ZBP-89 consensus-binding sites in promoter 1a (SCL-1a) or 1a11b (SCL-1a/b) were
mutated. Background luciferase activity was obtained using the control promoter-less vector pGL2. Abbreviation: WT, wild type.
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progenitors is likely caused by suppressed expression of one or
both of these factors.
Ablation of ZBP-89 in hematopoietic cells following com-
petitive transplantation of whole BM from CD45.21 ZBP-89ﬂ/ﬂ-
MxCre1 or ZBP-89ﬂ/ﬂ-MxCre2 (control) mice and pIpC treatment
again lead to the early drop in circulating CD411 cells at 3
weeks post-pIpC, similar to that observed in non transplanted
ZBP-89 CKO mice in the steady state. Follow-up of primary BMT
recipient mice, however, revealed a signiﬁcant and persistent
drop in circulating CD11b1 cells and an increase in B2201 cells
by 24 weeks post-transplant (Fig. 4C), together with a signiﬁ-
cant decrease in GMP and an increase in Pre-B BM progenitors
(Fig. 4D, 4E). The reciprocal changes in the progenitor cell pools
were also seen earlier (by 6 weeks) following secondary trans-
plantation, which persisted for at least 30 weeks (Fig. 5A). The
above lineage anomalies were reproduced in vitro by stable
knock down of ZBP-89 in the multipotent A4 cells (Table 1), sug-
gesting that the changes in the hematopoietic progenitors
observed in whole animals are cell-autonomous, and directly
related to loss of ZBP-89.
Selective transcriptional proﬁling showed increased PU.1
and suppressed GATA1 and SCL expression in MPP, CMP, and
MEP from ZBP-89 CKO mice (Figs. 2B, 5D) and in ZBP-89-
silenced A4 cells (Fig. 5E). These changes are expected to
favor development of the myeloid lineage, based on the
binary model of HSC fate decisions. Yet the measured out-
come was a reduction in the myeloid lineage, with a recipro-
cal increase in the B lymphoid lineage. One potential
explanation is the observed concomitant reduction of C/
EBPa in ZBP-89-deﬁcient myeloid progenitors (Fig. 5D), which
is also observed in ZBP-89-silenced A4 cells (Fig. 5E). The
reduction of C/EBPa in GMP compartment could compromise
the ability of PU.1 to access the autoregulatory 212 kb
enhancer element in this pool, which is necessary for its
commitment to the myelomonocytic cell lineage [5, 26]. This
myeloid lineage defect, which is not seen under steady state
conditions, is readily uncovered under the replicative stress
imposed by serial BMT, which could lead to exhaustion of
the GMP pool [39]. Formation of a complex of PU.1/E2A/
FOXO1 on the 214 kb URE in ZBP-89-deﬁcient CLP, where
PU.1 is also upregulated, appears sufﬁcient, however, for
growth and differentiation of the B cell lineage [26, 40, 41],
enhanced in this case by the concomitant upregulation of
FOXO1 in this population.
CHIP and luciferase reporter assays show that ZBP-89 acts
directly to repress PU.1 while activating both SCL and GATA1,
consistent with the lineage anomalies induced in vitro by loss
of ZBP-89 in A4 cells. The reciprocal regulation of C/EBPa and
FOXO1 by ZBP-89 in hematopoietic progenitors that is seen
both in vivo (Figs. 2B, 5D), and in vitro (Fig. 5E) may also be
direct (both promoters have potential ZBP-89 binding motifs)
or indirect, driven by modulated expression of one or more of
the other regulated genes.
CONCLUSION
In conclusion, we have provided evidence that ZBP-89 plays
an important role in stress hematopoiesis in adult mice.
Identiﬁcation of ZBP-89 as an important modulator of key
lineage-determining genes provides new insights into the
genetic programs that underlie lineage decisions in adult
hematopoiesis under steady state and stress conditions.
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